Lataa...
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type of cancers...
Tallennettuna:
| Julkaisussa: | Mol Cancer |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6833286/ https://ncbi.nlm.nih.gov/pubmed/31690319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-019-1091-2 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|